Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dobrowolny udział w badaniu i podpisanie świadomej zgody
- •Ogólny stan zdrowia oceniony na 0 lub 1 w skali ECOG
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Zaawansowany lub rozsiewny rak piersi, niezdolny do operacji
- •Co najmniej jeden widoczny guz do zmierzenia
- •Prawidłowe wyniki badań laboratoryjnych funkcji organów
- •Zgoda na stosowanie skutecznej antykoncepcji
✗ Disqualifies
- •Zapalne formy raka piersi
- •Nieodpowiedniość do hormonalnego leczenia raka
- •Historia innych nowotworów przed badaniem
- •Przyjmowanie tradycyjnych chińskich leków przeciwnowotworowych
- •Nie wyzdrowienie po operacji przed badaniem
- •Udział w innym badaniu klinicznym przed tym badaniem
- •Ciąża lub karmienie piersią
- •Poważne choroby serca lub zakrzepica przed badaniem
- •Zakażenie wirusem zapalenia wątroby B, C lub HIV
- •Uczulenie na składniki badanego leku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- May 5, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (25)
Anhui provincial hospital
Hefei, China
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Affiliated Cancer Hospital, Sun Yat-sen University
Guangzhou, China
Liuzhou people's Hospital
Liuzhou, China
Anyang Cancer Hospital
Anyang, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Harbin Medical University cancer Hospital
Harbin, China
Xiangyang Central Hospital
Xiangyang, China
Jiangsu Province Hospital
Nanjing, China
Jilin Cancer Hospital
Changchun, China
The first hospital of Jilin University
Changchun, China
General Hospital of Ningxia Medical University
Yinchuan, China
The second people's hospital of neijiang
Neijiang, China
Cancer Hospital of Xinjiang Medical University
Ürümqi, China
Zhejiang cancer Hospital
Hangzhou, China
Peking Union Medical College Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Chongqing University Three Gorges Hospital
Chongqing, China
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute
Nanning, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Xi'An International Medical Cancer Hospital
Xi'an, China
Henan Cancer Hospital
Zhengzhou, China
Trial contact
Shusen Wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.